Related references
Note: Only part of the references are listed.Why Test for Proportional Hazards?
Mats J. Stensrud et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
The T cell differentiation landscape is shaped by tumour mutations in lung cancer
Ehsan Ghorani et al.
NATURE CANCER (2020)
Clinical Impact of Tumor Mutational Burden in Neuroblastoma
William L. Hwang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC.
Sushma Jonna et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group
T. Eder et al.
EUROPEAN JOURNAL OF CANCER (2019)
Correlations between microsatellite instability and the biological behaviour of tumours
Guang Yang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
The mutational footprints of cancer therapies
Oriol Pich et al.
NATURE GENETICS (2019)
Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
Hao-Xiang Wu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report
Yuki Owada-Ozaki et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma
Min Yuen Teo et al.
CLINICAL CANCER RESEARCH (2017)
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
Noemi Andor et al.
NATURE MEDICINE (2016)
Clonal evolution of glioblastoma under therapy
Jiguang Wang et al.
NATURE GENETICS (2016)
Classification and characterization of microsatellite instability across 18 cancer types
Ronald J. Hanse et al.
NATURE MEDICINE (2016)
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Luc G. T. Morris et al.
ONCOTARGET (2016)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Evolutionary dynamics of cancer in response to targeted combination therapy
Ivana Bozic et al.
ELIFE (2013)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The role of chromosomal instability in tumor initiation
MA Nowak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)